Shaleigh Smith

Shaleigh Smith

Auto-generated profile, based on publicly available information

Shaleigh Smith

Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2022 in Cell
Verified
Journal Article
Closed access
BNBastien Nguyen
Bastien Nguyen
CFChristopher Fong
Christopher Fong
ALAnisha Luthra
Anisha Luthra
SSShaleigh A. Smith
Shaleigh A. Smith
RDRenzo G. DiNatale
Renzo G. DiNatale
NSNikolaus Schultz
Nikolaus Schultz

15 June 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
BNBenjamin Nacev
Benjamin Nacev
FSFrancisco Sanchez-Vega
Francisco Sanchez-Vega
SSShaleigh A. Smith
Shaleigh A. Smith
CACristina R. Antonescu
Cristina R. Antonescu
EREvan Rosenbaum
Evan Rosenbaum
WTWilliam D. Tap
William D. Tap
The genetic, biologic, and clinical heterogeneity of sarcomas poses a challenge for the identification of therapeutic targets, clinical research, and advancing patient care. Because there are > 100 sarcoma subtypes, in-depth genetic studies have focused on one or a few subtypes. Herein, we report a comparative genetic analysis of 2,138 sarcomas representing 45 pathological entities. This cohort is prospectively analyzed using targeted sequencing to characterize subtype-specific somatic alterations in targetable pathways, rates of whole genome doubling, mutational signatures, and subtype-agnostic genomic clusters. The most common alterations are in cell cycle control andTP53, receptor tyrosine kinases/PI3K/RAS, and epigenetic regulators. Subtype-specific associations includeTERTamplification in intimal sarcoma and SWI/SNF alterations in uterine adenosarcoma. Tumor mutational burden, while low compared to other cancers, varies between and within subtypes. This resource will improve sarcoma models, motivate studies of subtype-specific alterations, and inform investigations of genetic factors and their correlations with treatment response.

1 September 2022 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
KAKanika Arora
Kanika Arora
TTThinh N. Tran
Thinh N. Tran
YKYelena Kemel
Yelena Kemel
MMMiika Mehine
Miika Mehine
YLYing L. Liu
Ying L. Liu
MBMichael F. Berger
Michael F. Berger
Accurate ancestry inference is critical for identifying genetic contributors of cancer disparities among populations. Although methods to infer genetic ancestry have historically relied upon genome-wide markers, the adaptation to targeted clinical sequencing panels presents an opportunity to incorporate ancestry inference into routine diagnostic workflows. We show that global ancestral contributions and admixture of continental populations can be quantitatively inferred using markers captured by the MSK-IMPACT clinical panel. In a pan-cancer cohort of 45,157 patients, we observed differences by ancestry in the frequency of somatic alterations, recapitulating known associations and revealing novel associations. Despite the comparable overall prevalence of driver alterations by ancestry group, the proportion of patients with clinically actionable alterations was lower for African (30%) compared with European (33%) ancestry. Although this result is largely explained by population-specific cancer subtype differences, it reveals an inequity in the degree to which different populations are served by existing precision oncology interventions. Significance: We performed a comprehensive analysis of ancestral associations with somatic mutations in a real-world pan-cancer cohort, including >5,000 non-European individuals. Using an FDA-authorized tumor sequencing panel and an FDA-recognized oncology knowledge base, we detected differences in the prevalence of clinically actionable alterations, potentially contributing to health care disparities affecting underrepresented populations. This article is highlighted in the In This Issue feature, p. 2483

21 July 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
JDJosephine K. Dermawan
Josephine K. Dermawan
CKCiara Kelly
Ciara Kelly
YYYingjiang Ye
Yingjiang Ye
SSShaleigh Smith
Shaleigh Smith
BJBhumika Jadeja
Bhumika Jadeja
CACristina R. Antonescu
Cristina R. Antonescu
Purpose: Traditional risk stratification schemes in gastrointestinal stromal tumors (GIST) were defined in the pre-imatinib era and rely solely on clinicopathologic metrics. We hypothesize that genomic-based risk stratification is prognostically relevant in the current era of tyrosine kinase inhibitor (TKI) therapeutics. Experimental Design: Comprehensive mutational and copy-number profiling using MSK-IMPACT was performed. We integrated clinicopathologic and genomic parameters and utilized an elastic-net penalized Cox proportional hazards machine learning model for outcome risk stratification. Results: A 3-tier genomic risk stratification model for recurrence-free survival (RFS) in 152 primary localized gastric and 80 small bowel GISTs was proposed. Gastric GISTs were classified as high risk if chr1p deletion or SDHB loss was present, and intermediate risk if chr14q deletion was present or KIT exon 11 mutation was absent. Small bowel GISTs were classified as high risk if MAX/MGA/MYC, CDKN2A, or RB1 alterations were present, and intermediate risk if chr1p deletion or chr5q amplification was present. Compared with conventional risk stratification, genomic risk stratification both upgrades and downgrades, suggesting that conventional risk stratification may underestimate or overtreat some high-risk and low-risk patients, respectively. Longitudinal sequencing detected most KIT-independent genomic alterations at baseline. Subanalysis in 26 SDH-deficient GISTs revealed that presence of TP53 mutations or chr1q amplifications portends worse RFS and disease-free survival. Conclusions: We developed a novel, next-generation genomic risk stratification model for primary gastric and small bowel GISTs, complementing traditional clinicopathologic models. Future independent validation of our model in external cohorts is essential.

16 September 2024
Verified
Other
Open access
PDF file
JDJosephine Kam Tai K. Dermawan
Josephine Kam Tai K. Dermawan
CKCiara Kelly
Ciara Kelly
YYYingjiang Ye
Yingjiang Ye
SSShaleigh Smith
Shaleigh Smith
BJBhumika Jadeja
Bhumika Jadeja
CACristina R. Antonescu
Cristina R. Antonescu
Supplementary Figure 3. Genomic risk groups versus tumor size and mitotic rate.

16 September 2024
Verified
Other
Open access
JDJosephine Kam Tai K. Dermawan
Josephine Kam Tai K. Dermawan
CKCiara Kelly
Ciara Kelly
YYYingjiang Ye
Yingjiang Ye
SSShaleigh Smith
Shaleigh Smith
BJBhumika Jadeja
Bhumika Jadeja
CACristina R. Antonescu
Cristina R. Antonescu
Supplementary Table S1. Metastasis Frequencies by Traditional vs. Genomic Risk Stratification Supplementary Table S2. List of gene level and chromosomal arm level genomic variables used in OncoCast. Supplementary Table S3-S4. Frequencies of genomic alterations by OncoCast risk groups in primary gastric and small bowel GISTs. Supplementary Table S5. Number and frequencies of specific KIT/PDGFRA mutations in primary localized gastric and small bowel GISTs.